Virax Biolabs Group Limited has announced a $5 million Private Placement to support working capital and corporate purposes, with H.C. Wainwright & Co. as the placement agent.
Virax Biolabs Group Limited has entered into agreements for a private placement of 12,500,000 ordinary shares at $0.40 each, expecting to raise $5 million. The proceeds will be used for working capital and corporate purposes. The offering is set to close on December 4, 2025, subject to conditions. H.C
Who to call at Virax Biolabs, and when
A new round usually means Virax Biolabs is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Virax Biolabs raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Virax Biolabs, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Virax Biolabs. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Virax Biolabs
Location
Lanarkshire, Scotland, United Kingdom
About
Virax Biolabs Group Limited is an innovative biotech company founded in 2013 that focuses on detecting immune responses and diagnosing viral diseases, distributing a range of in-vitro diagnostic test kits while developing proprietary T-Cell Test technology aimed at providing an immunology profiling platform to assess individual immune risk against major global viral threats, including COVID-19, Monkeypox, Hepatitis B, Malaria, Herpes, and Human Papillomavirus.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Virax Biolabs raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LanarkshireManufacturingBiotechnologyHealth CareTherapeutics